As of 2025-06-13, the Intrinsic Value of Jazz Pharmaceuticals PLC (JAZZ) is 212.55 USD. This JAZZ valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 110.29 USD, the upside of Jazz Pharmaceuticals PLC is 92.70%.
The range of the Intrinsic Value is 108.41 - 772.40 USD
Based on its market price of 110.29 USD and our intrinsic valuation, Jazz Pharmaceuticals PLC (JAZZ) is undervalued by 92.70%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 108.41 - 772.40 | 212.55 | 92.7% |
| DCF (Growth 10y) | 128.87 - 804.82 | 235.61 | 113.6% |
| DCF (EBITDA 5y) | 43.31 - 110.12 | 72.77 | -34.0% |
| DCF (EBITDA 10y) | 71.76 - 150.99 | 105.78 | -4.1% |
| Fair Value | 93.21 - 93.21 | 93.21 | -15.49% |
| P/E | 105.45 - 238.48 | 171.61 | 55.6% |
| EV/EBITDA | 57.05 - 219.19 | 127.66 | 15.7% |
| EPV | 148.75 - 220.73 | 184.74 | 67.5% |
| DDM - Stable | 74.33 - 249.62 | 161.97 | 46.9% |
| DDM - Multi | 56.21 - 149.03 | 81.91 | -25.7% |
| Market Cap (mil) | 6,797.48 |
| Beta | 0.94 |
| Outstanding shares (mil) | 61.63 |
| Enterprise Value (mil) | 10,303.01 |
| Market risk premium | 4.60% |
| Cost of Equity | 9.09% |
| Cost of Debt | 7.35% |
| WACC | 6.97% |